Product Name

Rotigotine

Name: Rotigotine
SKU: 92206-54-7

CAS Number

92206-54-7

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Rotigotine

CAS Number:

92206-54-7

Indication:

For use/treatment in neurologic disorders and parkinson’s disease as well as moderate-to-severe primary Restless Legs Syndrome.

Mode of Action:

Rotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours. A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine

Pharmacodynamics:

There is no indication of a QT/QTc prolonging effect of Neupro in doses up to 24 mg/24 hours. The effects of Neupro at doses up to 24 mg/24 hours (supratherapeutic doses) on the QT/QTc interval was evaluated in a double-blind, randomized, placebo- and positive-controlled (moxifloxacin 400 mg IV, single dose) parallel-group trial with an overall treatment period of 52 days in male and female patients with advanced-stage Parkinson's disease. Assay sensitivity was confirmed by significant QTc prolongation by moxifloxacin.

Metabolism:

Hepatic (CYP-mediated).

Toxicity:

The most likely symptoms of overdose would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions, and other signs of excessive dopaminergic stimulation.

IUPAC:

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5, 6, 7, 8-tetrahydronaphthalen-1-ol

ATC:

N04BC09

PubChem:

57537

DrugBank:

DB05271

Formula:

C₂₅H₃₇NO₄

Molecular Mass:

315.473

SMILES:

CCCN(CCC1=CC=CS1)C1CCC2=C(C1)C=CC=C2O

InChi:

KFQYTPMOWPVWEJ-UHFFFAOYSA-N

General Reference:

Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinsonês disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007 Oct 12;. Pubmed
Chen JJ, Swope DM, Dashtipour K, Lyons KE: Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinsonês disease. Pharmacotherapy. 2009 Dec;29(12):1452-67. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

LGM pharma’s unique mix of API sourcing and CDMO services is fueling robust growth

Rotigotine

92206-54-7

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product